Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report

Area of Science:

• Pharmacology
• Clinical Medicine
• Neurology

Background:

• Direct oral anticoagulants (DOACs) are established for stroke prevention in atrial fibrillation (AF).
• The co-administration of Levetiracetam with DOACs has raised concerns regarding potential drug interactions.
• Clinical relevance of the Levetiracetam-DOAC interaction remains debated.

Observation:

• A case report details a 54-year-old male with AF, cirrhosis, and seizures requiring Dabigatran therapy.
• Assessment of Dabigatran plasma concentration was performed due to concurrent Levetiracetam use.
• No significant reduction in trough Dabigatran plasma levels was observed.

Findings:

• The study found no clinically relevant reduction in trough Dabigatran plasma concentration despite concomitant Levetiracetam use.
• A potential strategy to increase peak Dabigatran levels involves delaying Levetiracetam administration.
• The patient experienced no ischemic or hemorrhagic events during a 32-month follow-up.

Implications:

• DOAC concentration monitoring may aid in tailoring anticoagulant therapy for vulnerable patient populations.
• This case suggests that the interaction between Levetiracetam and Dabigatran may be less clinically significant than previously feared.
• Further research into personalized DOAC dosing strategies is warranted, particularly in patients with comorbidities.